Phase II evaluation of metoprine with leucovorin rescue in patients with advanced colorectal carcinoma.

Abstract

In a phase II trial 24 patients with measurable metastatic colorectal carcinoma were treated every 2 weeks with high-dose metoprine at 175 mg/m2 and leucovorin rescue. Hematologic toxicity was mild; the limiting toxicity was CNS, occurring in 54% of the patients. No responses were observed, but four patients had disease stabilization. High-dose metoprine with leucovorin rescue appears ineffective in previously treated patients with colorectal carcinoma in the dose and schedule used in this study.

• Authors: G Lynch, V Currie, N Kemeny
• Journal: Cancer clinical trials (Cancer Clin Trials) Vol. 4 Issue 3 Pg. 281-3 ( 1981) ISSN: 0190-1206 [Print] United States
• PMID: 6974612 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• metoprine
• Leucovorin
• Pyrimethamine

Topics

• Adult
• Aged
• Antineoplastic Agents (adverse effects, therapeutic use)
• Colonic Neoplasms (drug therapy)
• Drug Evaluation
• Drug Therapy, Combination
• Female
• Humans
• Leucovorin (therapeutic use)
• Male
• Middle Aged
• Neoplasm Metastasis
• Pyrimethamine (adverse effects, analogs & derivatives, therapeutic use)
• Rectal Neoplasms (drug therapy)